Southeast Asia’s E-Commerce to Reach New Heights, Driven by Digital Payments and Cross-Border Commerce Growth
11.3.2025 08:00:00 CET | Business Wire | Press Release
The latest InfoBrief by market intelligence firm IDC, commissioned by global payments platform 2C2P and Antom, revealed Southeast Asia’s (SEA’s) ecommerce market is projected to reach US$325 billion by 2028, fuelled by the rapid adoption of digital payments and regional interoperability, unlocking more opportunities in cross-border commerce for businesses.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250311192743/en/
Uncover trends and opportunities in Southeast Asia's digital economy (Graphic: Business Wire)
This year’s research paper, “How Southeast Asia Buys and Pays 2025”, marks the fourth edition of the IDC InfoBrief since 2021. IDC surveyed 600 respondents across six Southeast Asia (SEA) markets – Indonesia, Philippines, Malaysia, Singapore, Thailand and Vietnam, examining the evolving digital payments landscape as a whole and in each market.1 As the fifth largest economy in the world, SEA’s exceptional growth trajectory is largely driven by its rapidly expanding e-commerce sector, underpinned by increasing digital payment adoption.
The research explores the region’s evolving digital payments landscape and provides a market-specific analysis of the payment trends in each market. It also sheds light on how these trends are reshaping business strategies and laying the foundation for future growth opportunities in the region.
Key highlights from the IDC InfoBrief:
It is critical to have a comprehensive understanding of SEA’s digital payment landscape to fully tap into this US$325b economy. To maximise reach within local markets, it is essential to offer customers their preferred payment methods to enhance the overall customer experience and drive higher conversion rates.
- Growth in ecommerce digital payments: By 2028, digital payments are expected to account for 94% of total e-commerce payments in Southeast Asia. The most significant growth can be seen in domestic payments (97.9%) and mobile wallets (94.9%), which have been instrumental in expanding the reach of ecommerce in regions that traditionally relied less on cards.
- Surge in Real-time payments (RTPs): RTPs will see an exponential growth in 2028, reaching over US$11 trillion. This is already evident in Singapore, where RTPs like PayNow are the third most supported payment methods according to surveyed merchants in 2024. The rise in RTPs in Southeast Asia is largely driven by government initiatives to reduce cash reliance and to promote lower-cost, fast payment methods which meet the needs of both consumers and merchants.
- Dominance of Mobile Wallets and Domestic Payments: Mobile wallets and domestic payments lead in popularity across Southeast Asia. In 2023, mobile wallets were the top choice in Indonesia, Malaysia, and Vietnam, while domestic payments dominated in Singapore and Thailand. This trend continued in 2024, with mobile wallets being the second most accepted payment method by surveyed merchants in Singapore and Philippines and the third in Indonesia and Thailand.
There are also significant opportunities across SEA in intra-SEA cross border commerce.
- Opportunities in cross-border commerce: Intra-SEA cross-border commerce is projected to reach $14.6 billion by 2028, a 2.8 times growth from 2023. Notably, except for Vietnam and Indonesia, average cross-border transaction values per customer surpass domestic values in SEA markets, highlighting significant opportunities for businesses operating in the region.
- Driving cross-border commerce with Regional Payment Connectivity (RPC): Cross-border commerce is further supported by initiatives such as the RPC, joined by all six markets in the SEA region. The collaboration aims to strengthen and streamline inter-country payments, focusing on the development of seamless, efficient, and cost-effective cross-border transactions.
- Higher returns in cross-border commerce: For 62% of surveyed SEA merchants who sold their services and products across borders, such transactions were, on average, 21% higher than domestic transactions. Merchants stand to reap significant rewards by looking beyond their shores and building up their capacity to cater to neighbouring markets.
- Untapped potential of intra-SEA trade: Despite its promising growth, intra-SEA trade remains underutilised, accounting for only a small fraction of total cross-border commerce in each market. To fully capitalise on this, merchants must gain a deeper understanding of the distinctive operating environments in each market while leveraging shared advantages. By strategically addressing these factors, businesses can unlock the full potential of intra-regional trade and drive sustainable growth.
Agnes Chua, Managing Director of Business and Product Development of 2C2P, stated, “Southeast Asia’s e-commerce landscape is evolving at a breathtaking pace. Merchants recognise the immense opportunities this growth brings them in driving e-commerce revenue, but also acknowledge the increasing complexity it brings to their operations. This includes common challenges such as customer support and issue resolution, payment gateway integration and technology issues. At 2C2P, we empower businesses to navigate these challenges with confidence by delivering payment solutions that simplify operations, enhance cross-border capabilities, and drive growth in the region’s rapidly expanding digital economy so merchants can quickly unlock new opportunities and thrive in this dynamic environment."
Gary Liu, General Manager of Antom, Ant International, said, “Southeast Asia is rapidly emerging as a global hub for digital commerce and innovation. As businesses expand across borders, seamless and efficient transactions are essential for maintaining competitiveness. At Antom, we see payments not just as infrastructure but as a catalyst for business growth. By working with 2C2P and other businesses within Ant International's ecosystem, we empower merchants with unified payment and digitisation solutions covering the full payment lifecycle while also exploring opportunities in global account services, financing, and treasury management to further support their expansion. Through close collaboration with local regulators and industry partners, we aim to unlock new opportunities for businesses of all sizes, helping them thrive in Southeast Asia's evolving digital economy."
About 2C2P
2C2P is a full-suite payments platform that empowers the world's leading enterprises to securely accept and make payments through one point of integration. Its extensive network spans across online, mobile and offline channels including over 600,000 alternative payment locations, enabling enterprises to reach their customers or recipients anywhere. 2C2P also provides value-added services such as issuing, 3D Secure, bill payments and digital goods to meet every business need.
Headquartered in Singapore with operations across Southeast Asia and Hong Kong, 2C2P is the preferred payments partner for airlines, online marketplaces, retailers and other enterprises. To learn more, please visit https://2c2p.com/.
About Antom
Ant International's Antom is the leading payment and digitisation services provider for merchants around the world. It offers unified, vertical-specific digital payment solutions to serve businesses of all sizes. Antom supports merchants in over 50 countries and regions, enabling them to connect with consumers in more than 200 markets, with the flexibility to accept payments in more than 100 currencies. Beyond payments, it provides digital marketing solutions and merchant digitisation services to help merchant streamline operations and enhance customer engagement. To learn more, please visit https://www.antom.com/.
1IDC InfoBrief, commissioned by 2C2P, How Southeast Asia Buys and Pays 2025, Doc #AP242491IB, February 2025
View source version on businesswire.com: https://www.businesswire.com/news/home/20250311192743/en/
Contacts
For media queries
Scott Lai
Scott.lai@antgroup.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom